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72* The CD73/adenosine pathway regulates gap junctional
intercellular communication in the CFTR-expressing Calu-3
airway cell line
L.K. Scheckenbach1, M. Chanson1. 1Pediatrics, Geneva University Hospitals,
Geneva, Switzerland
cAMP dependent stimulation of protein kinase A by protease-activated receptors
(PAR) and adenosine receptors (A2B) regulates the activity of CFTR in airway
epithelial cells. This activity is required to maintain airway surface liquid volume
and mucociliary clearance. Gap junction channels form small aqueous pores
between adjacent cells allowing for the direct exchange of ions, metabolites and
second messengers, including cAMP.
By combining electrophysiological and pharmacological approaches, we found a
link between cAMP-dependent stimulation of A2B receptors and gap junctional
intercellular communication (GJIC) in Calu-3 cell monolayers. Adenosine (ADO)
is formed following hydrolysis of extracellular nucleotides by the membrane ectoen-
zyme CD73. Stimulation of Calu-3 cells with aminopterine (AMT), a methotrexate
analog which has previously been shown to increase CD73 activity, enhanced GJIC.
In contrast, inhibition of CD73 activity with AMP-CP decreased GJIC. These
experiments suggest that CD73 is expressed in Calu-3 cells and that its endogenous
activity releases ADO to stimulate GJIC. Thus, the transfer of cAMP between cells
through gap junction channels may be regulated by the CD73/ADO pathway. CD73
was also detected by immunoﬂuoresence in mouse upper airways. Regarding the
key role of CD73 in regulating the ATP/ADO balance, this phenomenon could
be relevant for maintenance of the airway epithelium function. In preliminary
experiments aimed at inhibiting GJIC with gap junction blockers and siRNA
techniques in Ussing chambers, we indeed observed decreased CFTR currents in
response to PAR activation. Experiments are underway to characterize further the
link between CFTR activation and GJIC.
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It has been reported an interdependency of b-adrenergic receptors (b-AR) and CFTR
in regulation of alveolar clearance. In addition, a modiﬁcation of b-AR density has
been reported in human CF airway without distinction of subtypes. However, until
now, only b1 and b2-AR have been identiﬁed in human airway.
Thus the aim of our study was ﬁrst to characterize the presence of b1, b2 and b3-
AR in control human bronchi (n = 5−7) by molecular and biochemical approaches
and second to compare their expression in CF bronchi (n = 4−6).
Using RT-PCR, we described the presence of mRNA encoding b1, b2 and b3-
AR in control and CF bronchi and the presence of proteins for these three
subtypes was conﬁrmed by western-blot. Immunohistology experiments showed a
b3-AR localisation mainly in epithelial cells with a major expression at the apical
membrane. In CF bronchi, we demonstrated, by real-time quantitative RT-PCR, that
b1-AR mRNA was signiﬁcantly decreased by 5.5 fold (p< 0.05). There were no
modiﬁcation of the level for b1-AR fully glycosylated protein, albeit a 2.7 fold
increase of the partially glycosylated form (p< 0.05) was observed. b2-AR mRNA
tended to decrease (p = 0.055) and its proteins level expression were divided by 7
(p< 0.05). By contrast, b3-AR mRNA tended to increase and its protein level was
enhanced by 2.8 fold (p< 0.05).
This study is the ﬁrst to characterize the presence of b3-AR in human bronchi.
Furthermore, we demonstrate a b-AR subtypes remodelling in CF with a decrease of
b2-AR and an upregulation of b3-AR. This work opens new ﬁelds of investigations,
such as the consequences of an imbalance in b2 and b3-AR expression. In addition,
the role of each b-AR subtype in the regulation of human CFTR wild-type and
mutated (DF508) must be investigated.
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Introduction: Lysosomal carboxypeptidase A (PPCA) is a serine protease with car-
boxypeptidase, amidase and esterase activity. PPCA is also an essential constituent
of the b-galactosidase and neuraminidase complexes. Neuraminidase is important
due to P. aeruginosa adherence to CF epithelial cells. Disturbed PPCA activity may
contribute to pathogenesis of bacterial infection in CF.
Aim of the study: the aim of the study was an assessment of PPCA activity in
mixed saliva in samples collected from cystic ﬁbrosis patients.
Materials and Methods: The study was performed in a group of 26 CF patients
(12F, 14M) and in a group of 28, age and sex matched healthy controls. 5ml of
mixed saliva was collected before and after stimulation of excretion with parafﬁn
pledgets. The protein and glycoprotein content was measured. The activity of PPCA
was assessed using Z-Phe-Ala substrate and measuring the amount of Ala released.
The association between CFTR mutation and PPCA activity was also assessed.
Results: The activity of PPCA was in controls 104.3±90.22 Ala nmol/mg protein
before stimulation and 130.8±88.71 Ala nmol/mg protein after stimulation. In CF
group the PPCA activity was 87.2±62.91 nmol/mg protein before stimulation and
195.0±246.79 nmol/mg protein after stimulation. No correlation between genotype
and PPCA activity was observed.
Conclusions: The PPCA activity was signiﬁcantly higher in CF group in compar-
ison to controls.
The study was supported from grant of Medical University of Bialystok no. 3–
43902L.
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The a7-nicotinic acetylcholine receptor (a7-nAChR) is characterized by an elevated
Ca permeability and may therefore regulate basic cell functions such as ion transport
across the airways. The a7-nAChR is located close to the CFTR protein at the
apex of ciliated cells. CFTR and a7-nAChR appear simultaneously in the human
airways at 13 weeks of development. In a7−/− mice, CFTR is no more detected at
the apex of ciliated cells. The nasal transepithelial potential (TEP) in a7−/− mice
is characterized by a higher basal level and a decreased response to forskolin.
Similarly, exposure of human airway cells to increasing concentrations of a-
bungarotoxin (a-Bgt), a speciﬁc antagonist of a7-nAChR, results in a decrease of
the basal TEP and of the response to forskolin. Using video-microscopic techniques,
we observed that increasing concentrations of a-Bgt induced a progressive decrease
of Cl− secretion and a decreased response to forskolin, both in cell cultures derived
from a normal epithelium and in a normal airway cell line. This effect was not
observed in cells derived from a patient with the DF508/3849 CFTR mutation and
in a CF airway cell line. The effect of a-Bgt was restored after CFTR transfection
and abolished in the presence of the CFTR inhibitor CFTRinh-172. Using X-ray
microanalysis of ion content in the cryo-ﬁxed mucus from mouse airways, we
observed a decreased concentration of the diffusible ions: Na, Cl, K and Ca in
a7−/− mice whereas Mg, P and S concentrations were unaltered. These results
suggest that a7-nAChR controls CFTR-dependent ion transport in the airways and
may be involved in the CF pathogenesis.
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